NLRP3 Protein Inhibitors Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight [Yahoo! Finance]
Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference
Owning 47% shares,institutional owners seem interested in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), [Yahoo! Finance]
Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update